Treats advanced prostate cancer. Sold as Camcevi, Camcevi Etm. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Leuprolide Mesylate (sold as Camcevi, Camcevi Etm), first approved May 25, 2021, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Camcevi | Part B | $31.4M | +3% | 8,673 |
| May 25, 2021 | CamceviNDA 211488 · New active ingredient | Accord | 4 | Marketed |
| Aug 25, 2025 | Camcevi EtmNDA 219745 · New formulation or manufacturer | Accord | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA